Beloved imagination, what I most like in you is your unsparing quality.
There remains madness, “the madness that one locks up,” as it has aptly been described. That madness or another... We all know, in fact, that the insane owe their incarceration to a tiny number of legally reprehensible acts and that, were it not for these acts their freedom (or what we see as their freedom) would not be threatened. I am willing to admit that they are, to some degree, victims of their imagination, in that it induces them not to pay attention to certain rules – outside of which the species feels threatened – which we are all supposed to know and respect. But their profound indifference to the way in which we judge them, and even to the various punishments meted out to them, allows us to suppose that they derive a great deal of comfort and consolation from their imagination, that they enjoy their madness sufficiently to endure the thought that its validity does not extend beyond themselves. And, indeed, hallucinations, illusions, etc., are not a source of trifling pleasure. The best controlled sensuality partakes of it, and I know that there are many evenings when I would gladly that pretty hand which, during the last pages of Taine’s L’Intelligence, indulges in some curious misdeeds. I could spend my whole life prying loose the secrets of the insane. These people are honest to a fault, and their naiveté has no peer but my own. Christopher Columbus should have set out to discover America with a boatload of madmen. And note how this madness has taken shape, and endured.
It is not the fear of madness which will oblige us to leave the flag of imagination furled.
The case against the realistic attitude demands to be examined, following the case against the materialistic attitude. The latter, more poetic in fact than the former, admittedly implies on the part of man a kind of monstrous pride which, admittedly, is monstrous, but not a new and more complete decay. It should above all be viewed as a welcome reaction against certain ridiculous tendencies of spiritualism. Finally, it is not incompatible with a certain nobility of thought.
We were told that Pfizer/BioNTech is a German company. But it is actually a German-Chinese company. Since I first found that Pfizer/BioNTech had an MOU with Fosun Pharmaceuticals, a major CCP-linked pharmaceutical company based in Shanghai, to make the Pfizer/BioNTech MRNA vaccines, I knew that with a bit more digging I would find China at the heart of these acts of war.
BioNTech’s SEC filing shows that the MOU with Fosun Pharmaceuticals includes an equity investment by Fosun in BioNTech. In other words, the CCP is an equity investor in BioNTech: “As part of the strategic alliance with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; Stock Symbol: 600196.SH, 02196.HK) whereby the two companies will work together on the development of BNT162 in China, Fosun agreed to make an equity investment which was received in mid-April 2020. The issuance of 1,580,777 ordinary shares with the nominal amount of k€ 1,581 was registered within the commercial register (Handelsregister) as of April 23, 2020.” Not only that but: “Ai-Min Hui, President of Global R&D, and Chief Medical Officer of Fosun Pharma said: ”We are closely working with BioNTech and regulatory authorities to evaluate the safety and efficacy of the vaccine candidate, in order to synchronize the development process in China with other countries, and to bring the vaccine to public as soon as possible, if the vaccine succeeds.” [https://www.sec.gov/Archives/edgar/data/1776985/000119312520210694/d54613d424b3.htm]
Fosun is not separate from the CCP; it is the CCP: Fosun acquired almost half of Sinopharm: “In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group (Chinese: 国药控股). […] In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment (Chinese: 国药产业投资) instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group (Sinopharm).” 2003年年报 [2003 Annual Report] (PDF). Fosun Industrial. 24 April 2004. Retrieved 5 August 2018– via Shanghai Stock Exchange website. [^ 国药集团复星联合成立首家混合所有制药企. 企业观察报 (in Chinese (China)). 4 August 2014. Retrieved 5 August 2018 – via Sina; ^ 2009年年报 [2009 Annual Report] (PDF). Fosun Pharmaceutical. 25 March 2010. Retrieved 5 August 2018 – via Shanghai Stock Exchange website.; ^ "Connection Transaction" (PDF) (Press release). Shanghai: Fosun International. 20 June 2008.]
Sinopharm, of course, as you see above, of which Fosun owns almost half, is owned in turn directly by the Chinese State and thus reports directly to the CCP.